Transforming growth factor β1 inhibits Fas ligand expression and subsequent activation-induced cell death in T cells via downregulation of c- Myc

Journal of Experimental Medicine

Volumn 189, Issue 2, 1999, Pages 231-239

  Genestier, Laurent ^a   Kasibhatla, Shailaja ^a   Brunner, Thomas ^a,b   Green, Douglas R ^a  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

Apoptosis; c Myc; Fas ligand; T cells; Transforming growth factor

Indexed keywords

4 HYDROXYTAMOXIFEN; ESTROGEN RECEPTOR; FAS LIGAND; MONOCLONAL ANTIBODY CD3; TRANSFORMING GROWTH FACTOR BETA1;

APOPTOSIS; ARTICLE; CELL DEATH; CHIMERA; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HYBRIDOMA; NORMAL HUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIGENS, CD3; APOPTOSIS; CELL CYCLE; DNA FRAGMENTATION; DOWN-REGULATION; FAS LIGAND PROTEIN; GENE EXPRESSION REGULATION; HYBRIDOMAS; MEMBRANE GLYCOPROTEINS; MICE; PROTO-ONCOGENE PROTEINS C-MYC; RECEPTORS, ESTROGEN; RECOMBINANT FUSION PROTEINS; RNA, MESSENGER; T-LYMPHOCYTES; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA;

EID: 0033579820     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.189.2.231     Document Type: Article

References (58)

1. Massague, J. 1990. The transforming growth factor-beta family. Annu. Rev. Cell Biol. 6:597-641.
2. Kasid, A., G.I. Bell, and E.P. Director. 1988. Effects of transforming growth factor-beta on human lymphokine-activated killer cell precursors. Autocrine inhibition of cellular proliferation and differentiation to immune killer cells. J. Immunol. 141:690-698.
3. Fontana, A., K. Frei, S. Bodmer, E. Hofer, M.H. Schreier, M.A. Palladino, Jr., and R.M. Zinkernagel. 1989. Transforming growth factor-beta inhibits the generation of cytotoxic T cells in virus-infected mice. J. Immunol. 143:3230-3244.
4. Bright, J.J., L.D. Kerr, and S. Sriram. 1997. TGF-beta inhibits IL-2-induced tyrosine phosphorylation and activation of Jak-1 and Stat 5 in T lymphocytes. J. Immunol. 159:175-183.
5. Moses, H.L., E.Y. Yang, and J.A. Pietenpol. 1990. TGF-beta stimulation and inhibition of cell proliferation: new mechanistic insights. Cell. 63:245-247.
6. Riedl, E., H. Strobl, O. Majdic, and W. Knapp. 1997. TGF-beta 1 promotes in vitro generation of dendritic cells by protecting progenitor cells from apoptosis. J. Immunol. 158: 1591-1597.
7. Swain, S.L., G. Huston, S. Tonkonogy, and A. Weinberg. 1991. Transforming growth factor-beta and IL-4 cause helper T cell precursors to develop into distinct effector helper cells that differ in lymphokine secretion pattern and cell surface phenotype. J. Immunol. 147:2991-3000.
8. Johns, L.D., K.C. Flanders, G.E. Ranges, and S. Sriram. 1991. Successful treatment of experimental allergic encephalomyelitis with transforming growth factor-beta 1. J. Immunol. 147:1792-1796.
9. Kuruvilla, A.P., R. Shah, G.M. Hochwald, H.D. Liggitt, M.A. Palladino, and G.J. Thorbecke. 1991. Protective effect of transforming growth factor beta 1 on experimental autoimmune diseases in mice. Proc. Natl. Acad. Sci. USA. 88: 2918-2921.
10. Santambrogio, L., G.M. Hochwald, B. Saxena, C.H. Leu, J.E. Martz, J.A. Carlino, N.H. Ruddle, M.A. Palladino, L.I. Gold, and G.J. Thorbecke. 1993. Studies on the mechanisms by which transforming growth factor-beta (TGF-beta) protects against allergic encephalomyelitis. Antagonism between TGF-beta and tumor necrosis factor. J. Immunol. 151:1116-1127.
11. Lee, H.M., and S. Rich. 1991. Co-stimulation of T cell proliferation by transforming growth factor-beta 1. J. Immunol. 147:1127-1133.
12. Rich, S., N. Van Nood, and H.M. Lee. 1996. Role of alpha 5 beta 1 integrin in TGF-beta 1-costimulated CD8+ T cell growth and apoptosis. J. Immunol. 157:2916-2923.
13. Cerwenka, A., H. Kovar, O. Majdic, and W. Holter. 1996. Fas- and activation-induced apoptosis are reduced in human T cells preactivated in the presence of TGF-beta 1. J. Immunol. 156:459-464.
14. Zhang, X., L. Giangreco, H.E. Broome, C.M. Dargan, and S.L. Swain. 1995. Control of CD4 effector fate: transforming growth factor beta 1 and interleukin 2 synergize to prevent apoptosis and promote effector expansion. J. Exp. Med. 182: 699-709.
15. Lynch, D.H., F. Ramsdell, and M.R. Alderson. 1995. Fas and FasL in the homeostatic regulation of immune responses. Immunol. Today. 16:569-574.
16. Alderson, M.R., T.W. Tough, T. Davis-Smith, S. Braddy, B. Falk, K.A. Schooley, R.G. Goodwin, C.A. Smith, F. Ramsdell, and D.H. Lynch. 1995. Fas ligand mediates activation-induced cell death in human T lymphocytes. J. Exp. Med. 181:71-77.
17. Brunner, T., R.J. Mogil, D. LaFace, N.J. Yoo, A. Mahboubi, F. Echeverri, S.J. Martin, W.R. Force, D.H. Lynch, C.F. Ware, et al. 1995. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature. 373:441-444.
18. Dhein, J., H. Walczak, C. Baumler, K.M. Debatin, and P.H. Krammer. 1995. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature. 373:438-441.
19. Ju, S.T., D.J. Panka, H. Cui, R. Ettinger, M. el-Khatib, D.H. Sherr, B.Z. Stanger, and A. Marshak-Rothstein. 1995. Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature. 373:444-448.
20. Yang, Y., M. Mercep, C.F. Ware, and J.D. Ashwell. 1995. Fas and activation-induced Fas ligand mediate apoptosis of T cell hybridomas: inhibition of Fas ligand expression by retinoic acid and glucocorticoids. J. Exp. Med. 181:1673-1682.
21. Shi, Y., J.M. Glynn, L.J. Guilbert, T.G. Cotter, R.P. Bissonnette, and D.R. Green. 1992. Role for c-myc in activation-induced apoptotic cell death in T cell hybridomas. Science. 257:212-214.
22. Bissonnette, R.P., A. McGahon, A. Mahboubi, and D.R. Green. 1994. Functional Myc-Max heterodimer is required for activation-induced apoptosis in T cell hybridomas. J. Exp. Med. 180:2413-2418.
23. Hueber, A.O., M. Zornig, D. Lyon, T. Suda, S. Nagata, and G.I. Evan. 1997. Requirement for the CD95 receptor-ligand pathway in c-Myc-induced apoptosis. Science. 278:1305-1309.
24. Ewen, M.E., H.K. Sluss, L.L. Whitehouse, and D.M. Livingston. 1993. TGF beta inhibition of Cdk4 synthesis is linked to cell cycle arrest. Cell. 74:1009-1020.
25. Hannon, G.J., and D. Beach. 1994. p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature. 371: 257-261.
26. Iavarone, A., and J. Massague. 1997. Repression of the CDK activator Cdc25A and cell-cycle arrest by cytokine TGF-beta in cells lacking the CDK inhibitor p15. Nature. 387:417-422.
27. Coffey, R.J., Jr., C.C. Bascom, N.J. Sipes, R. Graves-Deal, B.E. Weissman, and H.L. Moses. 1988. Selective inhibition of growth-related gene expression in murine keratinocytes by transforming growth factor beta. Mol. Cell. Biol. 8:3088-3093.
28. Pietenpol, J.A., R.W. Stein, E. Moran, P. Yaciuk, R. Schlegel, R.M. Lyons, M.R. Pittelkow, K. Munger, P.M. Howley, and H.L. Moses. 1990. TGF-beta 1 inhibition of c-myc transcription and growth in keratinocytes is abrogated by viral transforming proteins with pRB binding domains. Cell. 61:777-785.
29. Ruegemer, J.J., S.N. Ho, J.A. Augustine, J.W. Schlager, M.P. Bell, D.J. McKean, and R.T. Abraham. 1990. Regulatory effects of transforming growth factor-beta on IL-2- and IL-4-dependent T cell-cycle progression. J. Immunol. 144: 1767-1776.
30. Ashwell, J.D., R.E. Cunningham, P.D. Noguchi, and D. Hernandez. 1987. Cell growth cycle block of T cell hybridomas upon activation with antigen. J. Exp. Med. 165:173-194.
31. Schneider, P., N. Holler, J.L. Bodmer, M. Hahne, K. Frei, A. Fontana, and J. Tschopp. 1998. Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J. Exp. Med. 187:1205-1213.
32. Benhamou, L.E., T. Watanabe, D. Kitamura, P.A. Cazenave, and P. Sarthou. 1994. Signaling properties of anti-immunoglobulin-resistant variants of WEHI-231 B lymphoma cells. Eur. J. Immunol 24:1993-1999.
33. Pear, W.S., G.P. Nolan, M.L. Scott, and D. Baltimore. 1993. Production of high-liter helper-free retroviruses by transient transfection. Proc. Natl. Acad. Sci. USA. 90:8392-8396.
34. Force, W.R., T.C. Cheung, and C.F. Ware. 1997. Dominant negative mutants of TRAF3 reveal an important role for the coiled coil domains in cell death signaling by the lymphotoxin-beta receptor. J. Biol. Chem. 272:30835-30840.
35. Littlewood, T.D., D.C. Hancock, P.S. Danielian, M.G. Parker, and G.I. Evan. 1995. A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins. Nucleic Acids Res. 23:1686-1690.
36. Nicoletti, I., G. Migliorati, M.C. Pagliacci, F. Grignani, and C. Riccardi. 1991. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J. Immunol. Methods. 139:271-279.
37. Shi, Y.F., B.M. Sahai, and D.R. Green. 1989. Cyclosporin A inhibits activation-induced cell death in T-cell hybridomas and thymocytes. Nature. 339:625-626.
38. Eilers, M., D. Picard, K.R. Yamamoto, and J.M. Bishop. 1989. Chimaeras of myc oncoprotein and steroid receptors cause hormone-dependent transformation of cells. Nature. 340:66-68.
39. Brunner, T., N.J. Yoo, D. LaFace, C.F. Ware, and D.R. Green. 1996. Activation-induced cell death in murine T cell hybridomas. Differential regulation of Fas (CD95) versus Fas ligand expression by cyclosporin A and FK506. Int. Immunol. 8:1017-1026.
40. Latinis, K.M., L.A. Norian, S.L. Eliason, and G.A. Koretzky. 1997. Two NFAT transcription factor binding sites participate in the regulation of CD95 (Fas) ligand expression in activated human T cells. J. Biol. Chem. 272:31427-31434.
41. Galaktionov, K., X. Chen, and D. Beach. 1996. Cdc25 cell-cycle phosphatase as a target of c-myc. Nature. 382:511-517.
42. Bodmer, S., K. Strommer, K. Frei, C. Siepl, N. de Tribolet, I. Heid, and A. Fontana. 1989. Immunosuppression and transforming growth factor-beta in glioblastoma. Preferential production of transforming growth factor-beta 2. J. Immunol. 143:3222-3229.
43. Inge, T.H., K.M. McCoy, B.M. Susskind, S.K. Barrett, G. Zhao, and H.D. Bear. 1992. Immunomodulatory effects of transforming growth factor-beta on T lymphocytes. Induction of CD8 expression in the CTLL-2 cell line and in normal thymocytes. J. Immunol. 148:3847-3856.
44. Smyth, M.J., S.L. Strobl, H.A. Young, J.R. Ortaldo, and A.C. Ochoa. 1991. Regulation of lymphokine-activated killer activity and pore-forming protein gene expression in human peripheral blood CD8+ T lymphocytes. Inhibition by transforming growth factor-beta. J. Immunol. 146:3289-3297.
45. Bissonnette, R.P., T. Brunner, S.B. Lazarchik, N.J. Yoo, M.F. Boehm, D.R. Green, and R.A. Heyman. 1995. 9-cis retinoic acid inhibition of activation-induced apoptosis is mediated via regulation of fas ligand and requires retinoic acid receptor and retinoid X receptor activation. Mol. Cell. Biol. 15:5576-5585.
46. Green, D.R., A. Mahboubi, W. Nishioka, S. Oja, F. Echeverri, Y. Shi, J. Glynn, Y. Yang, J. Ashwell, and R. Bissonnette. 1994. Promotion and inhibition of activation-induced apoptosis in T-cell hybridomas by oncogenes and related signals. Immunol. Rev. 142:321-342.
47. Luscher, B., and R.N. Eisenman. 1990. New light on Myc and Myb. Part I. Myc. Genes Dev. 4:2025-2035.
48. Evan, G.I., A.H. Wyllie, C.S. Gilbert, T.D. Littlewood, H. Land, M. Brooks, C.M. Waters, L.Z. Penn, and D.C. Hancock. 1992. Induction of apoptosis in fibroblasts by c-myc protein. Cell. 69:119-128.
49. Klefstrom, J., E. Arighi, T. Littlewood, M. Jäättel, E. Saksela, G.I. Evan, and K. Alitalo. 1997. Induction of TNF-sensitive cellular phenotype by c-Myc involves p53 and impaired NF-kappaB activation. EMBO (Eur. Mol. Biol. Organ.) J. 16: 7382-7392.
50. Boehme, S.A., and M.J. Lenardo. 1993. Propriocidal apoptosis of mature T lymphocytes occurs at S phase of the cell cycle. Eur. J. Immunol. 23:1552-1560.
51. Arsura, M., M. Wu, and G.E. Sonenshein. 1996. TGF beta 1 inhibits NF-kappa B/Rel activity inducing apoptosis of B cells: transcriptional activation of I kappa B alpha. Immunity. 5:31-40.
52. Fischer, G., S.C. Kent, L. Joseph, D.R. Green, and D.W. Scott. 1994. Lymphoma models for B cell activation and tolerance. X. Anti-mu-mediated growth arrest and apoptosis of murine B cell lymphomas is prevented by the stabilization of myc J. Exp. Med. 179:221-228.
53. Sonenshein, G.E. 1997. Down-modulation of c-myc expression induces apoptosis of B lymphocyte models of tolerance via clonal deletion. J. Immunol. 158:1994-1997.
54. Warner, G.L., J.W. Ludlow, D.A. Nelson, A. Gaur, and D.W. Scott. 1992. Anti-immunoglobulin treatment of murine B-cell lymphomas induces active transforming growth factor beta but pRB hypophosphorylation is transforming growth factor beta independent. Cell Growth Differ. 3:175-181.
55. Wu, M., M. Arsura, R.E. Bellas, M.J. FitzGerald, H. Lee, S.L. Schauer, D.H. Sherr, and G.E. Sonenshein. 1996. Inhibition of c-myc expression induces apoptosis of WEHI 231 murine B cells. Mol. Cell. Biol. 16:5015-5025.
56. Beverley, P.C. 1990. Is T-cell memory maintained by cross-reactive stimulation? Immunol. Today. 11:203-205.
57. Gray, D., and P. Matzinger. 1991. T cell memory is short-lived in the absence of antigen. J. Exp. Med. 174:969-974.
58. Shull, M.M., I. Ormsby, A.B. Kier, S. Pawlowski, R.J. Diebold, M. Yin, R. Allen, C. Sidman, G. Proetzel, D. Calvin, et al. 1992. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature. 359:693-699.